Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALSAM-1: KarXT in manic episodes of bipolar I disorder
jRCT2041250071Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing KarXT with Placebo (2 arms). Primary endpoint: Change from baseline in Young Mania Rating Scale (YMRS) score at Week 3. Started Aug 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on jRCT2041250071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250071.